Stifel Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett has initiated coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and a price target of $11.
October 19, 2023 | 8:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gracell Biotechnologies has been initiated with a Buy rating by Stifel with a price target of $11.
The initiation of coverage by Stifel with a Buy rating and a price target of $11 indicates a positive outlook for Gracell Biotechnologies. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100